Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

被引:17
|
作者
Boulin, Mathieu [1 ,2 ]
Adam, Heloise [1 ]
Guiu, Boris [2 ,3 ]
Aho, Ludwig Serge [4 ]
Cercueil, Jean-Pierre [2 ,3 ]
Di Martino, Cyrille [4 ]
Fagnoni, Philippe [1 ,2 ]
Minello, Anne [2 ,5 ]
Jouve, Jean Louis [2 ,5 ]
Hillon, Patrick [2 ,5 ]
Bedenne, Laurent [2 ,5 ]
Lepage, Come [2 ,5 ]
机构
[1] CHU Univ Hosp, Dept Pharm, F-21000 Dijon, France
[2] Univ Burgundy, F-21079 Dijon, France
[3] CHU Univ Hosp, Dept Radiol, F-21000 Dijon, France
[4] Georges Francois Leclerc Anticanc Ctr, Dept Pharm, F-21079 Dijon, France
[5] CHU Univ Hosp, Dept Hepatogastroenterol, F-21079 Dijon, France
关键词
Hepatocellular carcinoma; Toxicity; Transarterial chemoembolisation; LIPIODOL CHEMOEMBOLIZATION; COHORT; TRIAL; MODEL;
D O I
10.1016/j.dld.2013.12.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim: To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods: All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade >= 4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic regression model. The robustness of the final model was confirmed using bootstrapping (500 replications). Results: 124 patients were included, median age was 67 years and 90% were male; 22 patients (18%) experienced severe TACE-related toxicity. Factors that independently predicted severe TACE-related toxicity in multivariate analysis were total tumour size (OR, 1.15 cm(-1); 95% CI, 1.04-1.26; p = 0.01), and high serum AST levels (OR, 1.10 per 10 IU/l; 95% CI, 1.01-1.21; p = 0.04). The results were confirmed by bootstrapping. Conclusions: Total tumour size and high serum AST levels were predictive factors of severe TACE-related toxicity in this hospital-based series of patients with unresectable HCC. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:358 / 362
页数:5
相关论文
共 50 条
  • [1] Outcomes of transarterial chemoembolisation for the treatment of advanced unresectable hepatocellular carcinoma
    Efthymiou, M.
    Roberts, S.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A248 - A248
  • [2] Transarterial Chemoembolisation Using Doxorubicin Beads for Unresectable Hepatocellular Carcinoma
    Poston, Graeme J.
    [J]. ONKOLOGIE, 2010, 33 (1-2): : 5 - 6
  • [3] Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma
    Boulin, Mathieu
    Ciboulet, Anne
    Guiu, Boris
    Maillard, Emilie
    Bonnetain, Franck
    Minello, Anne
    Gagnaire, Alice
    Lepage, Come
    Krause, Denis
    Hillon, Patrick
    Bedenne, Laurent
    Cercueil, Jean-Pierre
    Chauffert, Bruno
    Jouve, Jean Louis
    [J]. DIGESTIVE AND LIVER DISEASE, 2011, 43 (11) : 905 - 911
  • [4] Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
    Kim, D. Y.
    Ryu, H. J.
    Choi, J. Y.
    Park, J. Y.
    Lee, D. Y.
    Kim, B. K.
    Kim, S. U.
    Ahn, S. H.
    Chon, C. Y.
    Han, K. -H.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (11) : 1343 - 1350
  • [5] Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
    Zhao, Shoujie
    Zhang, Xiangnan
    Wang, Mengmeng
    Tan, Kai
    Dou, Weijia
    Fan, Qingling
    Li, Huichen
    Du, Xilin
    Liu, Lei
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (09)
  • [6] TRANSARTERIAL CHEMOEMBOLISATION IN PATIENTS WITH METASTATIC HEPATOCELLULAR CARCINOMA
    Bettinger, D.
    Spode, R.
    Thimme, R.
    Schultheiss, M.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S460 - S460
  • [7] The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma
    Cabrera, R.
    Pannu, D. S.
    Caridi, J.
    Firpi, R. J.
    Soldevila-Pico, C.
    Morelli, G.
    Clark, V.
    Suman, A.
    George, T. J., Jr.
    Nelson, D. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (02) : 205 - 213
  • [8] Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study
    Tong, Huan
    Wei, Bo
    Chen, Shuang
    Xie, Yong-Mei
    Zhang, Ming-Guang
    Zhang, Lin-Hao
    Huang, Zhi-Yin
    Tang, Cheng-Wei
    [J]. ONCOTARGET, 2017, 8 (29) : 48303 - 48312
  • [9] Transarterial chemoembolisation in hepatocellular carcinoma [Transarterielle perkutane Chemoembolisation beim Leberzellkarzinom]
    Petersen J.
    Henninger B.
    Glodny B.
    Jaschke W.
    [J]. Wiener Medizinische Wochenschrift, 2013, 163 (5-6) : 123 - 127
  • [10] Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
    He, MinKe
    Li, Qing
    Shen, JingXian
    Tan, GuoSheng
    Li, QiJiong
    Lai, JiaYing
    Wei, Wei
    Zhang, YaoJun
    Zou, RuHai
    Chen, MinShan
    Guo, RongPing
    Shi, Ming
    [J]. CANCER MEDICINE, 2019, 8 (09): : 4200 - 4213